Innogenetics secures key patent for hepatitis B drug resistance testing

08-Feb-2008

Innogenetics announced that the United States Patent Office has granted a key patent for hepatitis B drug resistance testing. This is the first granted US patent covering a critical mutation leading to hepatitis B viral drug resistance. US patent 7,313,357 covers an HBV virus with the YMDD mutation and, therefore, any method using this mutation for drug resistance testing. Drug resistance testing is now highly recommended for all currently available hepatitis B antivirals such as lamivudine, adefovir, and entecavir. The patent broadens Innogenetics patent position in the field for at least 10 years.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances